Norvium Bioscience Company Profile

✉ Email this page to a colleague

NORVIUM BIOSCIENCE has two hundred and thirty-nine approved drugs.

There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.

There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and thirty-five supplementary protection certificates in seventeen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	FOSPHENYTOIN SODIUM	fosphenytoin sodium	INJECTABLE;INJECTION	078736-001	Jun 8, 2010		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET;ORAL	075976-002	Jan 24, 2002		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	077375-001	May 21, 2010		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	RIZATRIPTAN BENZOATE	rizatriptan benzoate	TABLET, ORALLY DISINTEGRATING;ORAL	078173-001	Dec 31, 2012		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993	RE34672	⤷ Sign Up
Norvium Bioscience	ASTELIN	azelastine hydrochloride	SPRAY, METERED;NASAL	020114-001	Nov 1, 1996	5,164,194*PED	⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993	RE30633	⤷ Sign Up
Norvium Bioscience	MENTAX	butenafine hydrochloride	CREAM;TOPICAL	020524-001	Oct 18, 1996	5,021,458	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Foam	0.12%	➤ Subscribe	2007-08-10
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Inhalation Solution	0.021% and 0.042%	➤ Subscribe	2005-10-19
➤ Subscribe	Foam	2%	➤ Subscribe	2009-07-30
➤ Subscribe	Topical Foam	0.05%	➤ Subscribe	2005-06-27
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2006-12-13
➤ Subscribe	Nasal Spray	0.125 mg base/spray	➤ Subscribe	2005-11-14

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
New Zealand	541526	⤷ Sign Up
Eurasian Patent Organization	014372	⤷ Sign Up
Argentina	051197	⤷ Sign Up
Canada	2578594	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0496835	SPC/GB96/053	United Kingdom	⤷ Sign Up	PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
1301519	11/2016	Austria	⤷ Sign Up	PRODUCT NAME: TENOFOVIRALAFENAMID ODER EIN SALZ ODER SOLVAT DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061/001-002 (MITTEILUNG) 20151123
0240228	SPC/GB97/086	United Kingdom	⤷ Sign Up	PRODUCT NAME: QUETIAPINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: UK 12619/0112 19970731; UK 12619/0113 19970731; UK 12619/0114 19970731
0984957	PA2011005,C0984957	Lithuania	⤷ Sign Up	PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.